TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05642377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGR4113
Description: Once-daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGR4113
Description: Once-daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGR4113
Description: Once-daily oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGR4113
Description: Twice-daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGR4113
Description: Twice-daily oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice-daily oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice-daily oral administration
Study: NCT05700266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban (2.5mg orally twice a day for 90 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel (300mg loading dose, then 75mg once daily for 90 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin (100mg once a day for 1 year)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin (100mg once a day for 1 year)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Risk Factor Management in both arms
Description: Risk factors for stroke (LDL, blood pressure, non-HDL cholesterol, diabetes, smoking, weight, and physical activity) will be monitored and managed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk Factor Management in both arms
Description: Risk factors for stroke (LDL, blood pressure, non-HDL cholesterol, diabetes, smoking, weight, and physical activity) will be monitored and managed
Study: NCT04772248

Intervention type: DRUG
Intervention: Tofacitinib
Description: First eligible prescription for treating rheumatoid arthritis (RA)

Intervention type: DRUG
Intervention: TNF Inhibitor
Description: First eligible prescription for treating rheumatoid arthritis (RA)
Study: NCT06078657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI110+Sintilimab
Description: IBI110, 200mg, intravenously on the first day of each cycle, every 3 weeks for 1 cycle (Q3W), and the maximum use time was 2 years.~Sintilimab, 200mg, intravenously on the first day of each cycle, every 3 weeks as a cycle (Q3W), and the maximum use time was 2 years.
Study: NCT05088473

Intervention type: OTHER
Intervention: Biological collection
Description: Collection of cerebrospinal fluid kappa and lambda free light chains and indexes

Intervention type: OTHER
Intervention: Biological collection
Description: Collection of cerebrospinal fluid kappa and lambda free light chains and indexes

Intervention type: OTHER
Intervention: Biological collection
Description: Collection of cerebrospinal fluid kappa and lambda free light chains and indexes

Intervention type: OTHER
Intervention: Biological collection
Description: Collection of cerebrospinal fluid kappa and lambda free light chains and indexes
Study: NCT05933109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal Therapy and Targeted memory reactivation during REM sleep
Description: Emerging evidence shows that REM sleep plays a causal role in extinction learning, emotion regulation and consolidation of emotionally positive memories. By using targeted memory reactivation (TMR), a known method where a sound S1 is associated with a waking experience (i.e., a positive outcome of imagery rehearsal therapy in this study) and strengthening it during REM sleep, the investigators want to accelerate the remission of traumatic nightmares and PTSD symptomatology.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Imagery Rehearsal Therapy
Description: These patients will receive the classic treatment of Imagery Rehearsal Therapy (IRT) for nightmares without association with the sound S1.
Study: NCT05249335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OST
Description: The subject will receive Orafang for colonoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2L-PEG/Asc
Description: The subject will receive 2L-PEG/Asc for colonoscopy
Study: NCT05840614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The remote family support program
Description: Remote family support programs consist of interpersonal psychotherapy (IPT) and family psychoeducation.~Each session consisted of a lecture, followed by role playing and supportive group therapy. In the first session, we informed the participants about the symptoms of eating disorders and mechanism of IPT; in the second session, we shared details about the characteristics of adolescents; and during the third and fourth sessions, we provided information on effective communication according to IPT.
Study: NCT04937101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine-Codeine
Description: When the filter tester is sensitive, he opened the random letter group envelope to the notification letter manager and jointly confirmed the classification of the message group. The test group used the chlorpheniramine beacon, the physiological surface was used, and the local lesions of fine particles were used in the focus. Injection therapy. No form of anesthesia is used during injection. A total of injection treatment, at intervals, each treatment and the last treatment, treatment and safety after 1 month.
Study: NCT04465136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CES, Alpha-Stim stimulator (Electromedical Products International, Inc., Mineral Wells, Texas, USA)
Description: CES is a brain stimulation device with 2 electrodes on the bilateral earlobe. It uses Alternating current to stimulate the brain including thalamus, vagus nerve system and influence EEG and neurotransmitters like gamma-aminobutyrate. Stimulation was applied at a current intensity that can be adjusted continuously to provide between 10 and 600 micro-ampere and frequency of 0.5Hertz for 60 minutes, everyday for 6 weeks, total 42 sessions.
Study: NCT06200025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cue-based speech therapy in virtual reality
Description: Treatment applied with virtual reality headsets to provide 3d visual and auditory cues to individuals in a virtual environment. A treatment environment where the provision of cues can be controlled by the therapist, interacting with 3d clues and receiving feedback on the accuracy of the named objects.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cue-based speech therapy
Description: Treatment involving the assessment of language skills and the presentation of communication strategies to the individual, including the use of personalized phonological cues.
Study: NCT04196114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STIMO-2 device implantation
Description: Implantation of SCS lead in epidural space and implantation of neurostimulator in abdominal region
Study: NCT05488860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide(scar)/5-ALA(others)
Description: For scar, the drug is triamcinolone acetonide.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezoelectric drived microneedling
Description: Piezoelectric drived microneedling

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-ALA (a photosensitizer for photodynamic therapy).
Description: For other diseases, the drug is 5-ALA (a photosensitizer for photodynamic therapy).
Study: NCT06406348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALIA-1758
Description: Intravenous or subcutaneous doses
Study: NCT06455982

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: reduced carbohydrate menu combined with ketogenic supplement
Description: Participants will eat a reduced carb menu for 2 months and they will take 15g of MCT in the morning and the evening for a total of 30g per day.
Study: NCT05137184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Description: Inhalation of Methoxyflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Intranasal Fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine hydrochloride
Description: Intravenous Morphine
Study: NCT06406348

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous or subcutaneous doses
Study: NCT05880056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerkardou (5 mg) & (10 mg)
Description: Bisoprolol oral dissolved film ODF(5 mg): equivalent to 5 mg of bisoprolol fumarate Bisoprolol oral dissolved film ODF (10 mg): equivalent to 10 mg of bisoprolol fumarate.
Study: NCT06562023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Patients will receive BTA injection within a period of 5 days after primary closure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mesotherapy
Description: Patients will receive mesotherapy growth factor serum with a derma pen within a period of 5 days after primary closure.
Study: NCT06560580

Intervention type: DRUG
Group type: OTHER
Intervention: 3% Diquafosol Sodium Eye Drops
Description: Each patient was prescribed 3% (5 mL: 150 mg) diquafosol sodium eye drops \[Diquas®, provided by Santen Pharmaceutical (China) Co., Ltd.\], recommended to instill one drop six times daily for 3 months. Follow-up examinations were conducted at baseline, 1 month, and 3 months after treatment initiation.

Intervention type: DRUG
Group type: OTHER
Intervention: 3% Diquafosol Sodium Eye Drops
Description: Each patient was prescribed 3% (5 mL: 150 mg) diquafosol sodium eye drops \[Diquas®, provided by Santen Pharmaceutical (China) Co., Ltd.\], recommended to instill one drop six times daily for 3 months. Follow-up examinations were conducted at baseline, 1 month, and 3 months after treatment initiation.
Study: NCT06561100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sub-symptomatic Adaptable Exercise Treatment (SAET)
Description: Each workout will be structured in a similar format. The first 5 minutes will be devoted to stretching and warm up exercises. Then the next 20 minute segment devoted to light to moderate aerobic exercise. The second 20 minutes of each exercise session will be composed of a series of 5 predetermined exercises that rotate every day. Each workout will have one or two alternatives that the patient can complete either for modification to accommodate a physical limitation or to optimize preference. Resistance training each day will include multi-joint functional movements along with stability work. The last five minutes of the session will include more mobility work, and/or cooling down.
Study: NCT05232409

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zeaxanthin
Description: The doses of zeaxanthin will be based on weight starting with 2 milligrams of zeaxanthin per kilogram of your body weight (mg/kg) followed by 4 mg/kg, 6 mg/kg, and finally 8 mg/kg. If a dose level is found to be unsafe, then a new group of patients will be treated at the midpoint dose between the not tolerated dose and the last tolerated dose. Zeaxanthin is supplied as 50 milligram capsules and a person's dose will be rounded to the nearest 50 milligrams.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Zeaxanthin Plus Pembrolizumab
Description: The doses of zeaxanthin will be based on weight starting with 2 milligrams of zeaxanthin per kilogram of your body weight (mg/kg) followed by 4 mg/kg, 6 mg/kg, and finally 8 mg/kg. If a dose level is found to be unsafe, then a new group of patients will be treated at the midpoint dose between the not tolerated dose and the last tolerated dose. Zeaxanthin is supplied as 50 milligram capsules and a person's dose will be rounded to the nearest 50 milligrams.~The dose of pembrolizumab will be administered at a fixed dose of 400 milligrams intravenous every 6 weeks which is an FDA approved dosing schedule to treat cancer patients with pembrolizumab.
Study: NCT04612608

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: upright bed
Description: moving the bed into an upright position
Study: NCT05112731

Intervention type: DIAGNOSTIC_TEST
Intervention: BAFF and MGO
Description: measurement of BAFF and MGO levels before reperfusion and after 3 months
Study: NCT06561100

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Control Group (SCG)
Description: Each workout will be 50-60 minutes long and participants are instructed to not do any other type of exercise that may elevate their heart rate. Modifications will be available for stretches that may be too advanced for the individual.
Study: NCT04670250

Intervention type: DIAGNOSTIC_TEST
Intervention: non invasive markers
Description: non invasive markers (IL6, serum ferritin, fecal lactoferrin) used for monitoring of newly diagnosed patients with ulcerative colitis
Study: NCT05255380

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and compassion-based practices; approximately 5-10 minutes two times/day
Description: The app-based (audio-guided) interventions consist of mindfulness and compassion-based practices that are selected to maximize their effect on stress targets. Interventions include, for example, practices that focus on the breath/body (e.g., 3-minute breathing space; compassionate body scan; five senses mediation), on increasing participants' inner resources (e.g., imaging a safe person or safe place), on reducing negative affect (e.g., self-compassion and acceptance-based practices), or on increasing positive emotions (e.g., gratitude practice; metta practices).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Mindful awareness and reporting of current thoughts and feelings, 2 times/day
Description: Participants are instructed to be mindful (pay attention) to their current thoughts and feelings and complete ecological momentary assessments of their current psychological stress states (e.g., stress appraisals, affect, perseverative cognitions, self-criticism, social connection)
Study: NCT05371665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Adapted Compass for Courage
Description: COMPASS is an indicated prevention and early intervention program for 8-13-year-old youth with higher anxiety. Our CAB has decided to adapt it as a universal prevention and early intervention for all NA youth in the tribal community. It is delivered across six weeks with 30 min weekly sessions. Youth engage in games (e.g., WorryHeads Board Game) and role-play reducing anxiety and stress in mildly challenging situations to provide in-vivo exposure. Session 1 involves introductions, relaxation training, and discussing emotions. Session 2 teaches youth about worries and how to handle them. Session 3 focuses on having conversations with others. Session 4 teaches youth how to be assertive (CAB identified this as an area of adaption in initial meetings). Session 5 teaches youth how to face their fears. Session 6 is a review session. Parents and teachers are sent notes of what youth learned in each session and asked to encourage youth to practice their learned skills.
Study: NCT05212285

Intervention type: DEVICE
Intervention: Inbody 570
Description: Bioelectrical Impedance Analysis with Inbody 570 (Inbody Co., Seoul, Korea) during each follow-up

Intervention type: DEVICE
Intervention: Inbody 570
Description: Bioelectrical Impedance Analysis with Inbody 570 (Inbody Co., Seoul, Korea) during each follow-up

Intervention type: DEVICE
Intervention: JAMAR Dynamometer
Description: Handgrip strength measurement using a JAMAR Dynamometer (JAMAR Co., Ltd., USA) during each follow-up

Intervention type: DEVICE
Intervention: JAMAR Dynamometer
Description: Handgrip strength measurement using a JAMAR Dynamometer (JAMAR Co., Ltd., USA) during each follow-up

Intervention type: RADIATION
Intervention: CT scan
Description: Chest and abdominal CT scan during each follow-up

Intervention type: RADIATION
Intervention: CT scan
Description: Chest and abdominal CT scan during each follow-up
Study: NCT05980156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine
Description: Treatment will be with DP (females less than 10 years old and all males) or chloroquine alone (females 10 years old or older).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Treatment of females 10 years old and older in Arm 1 and treatment of all participants in Arm 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Treatment of females 10 years old and older in Arm 1 and treatment of all participants in Arm 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine pyrimethamine
Description: Treatment will be with SP and chloroquine (females less than 10 years old and all males) or chloroquine alone (females 10 years old or older).
Study: NCT05667272

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06347562

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Optical Genome Mapping
Description: to evaluate the capability of OGM, its usefulness in clinical diagnosis, and its impact on genetic counseling.
Study: NCT04710381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMUNOR
Description: The intervention consists of the administration of IMUNOR as prevention against COVID-19 disease
Study: NCT05801497

Intervention type: PROCEDURE
Intervention: Balneotherapy
Description: The patients in the BT group will be treated with 12 daily immersion in a bathtub or in a pool at a 37-38°C or with a combination of bath and mud-packs to carry out in a period of two weeks.~The application of mud-packs will follow the standard procedure with a duration of 15-20 minutes at 40-45°C. After the treatment, patients will have 20-30 minutes of bed rest. To be included in the study, thermal interventions must be carried out with sulfourous, solfate, bicarbonate, saline or sodium chloride and arsenical-ferruginous mineral waters, according to the classification by Marotta and Sica.
Study: NCT06402539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: family-centered empowerment program
Description: The intervention will be carried out face to face in the Orthopedics and Traumatology outpatient clinic, and some interviews will be held by phone. The first interview is on the day the patient will be approved in the anesthesia department, the second interview is when the patient is admitted to the ward, the third interview is after the surgery and the fourth interview is in the ward on the day of discharge, the fifth interview is by phone 1 week after discharge, the sixth interview is at the outpatient clinic when the patient comes for a check-up 2 weeks after discharge, and the seventh interview is at the time of discharge. The eighth interview will be held by phone in the 3rd week after discharge, and the eighth interview will be held in the outpatient clinic in the 4th week after discharge.
Study: NCT03733197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culture Specific
Description: We anticipate the culture-specific arm developed minimally will include two core components: barbers as motivational interviewers, and (2) fecal immunochemical test (FIT) kits distributed by barbers. If we choose this route for the culture-specific arm, preliminary data from our barbers suggest I teach the barbers the MI technique using content that stems from Aim 1 findings. Additional components for this arm may be developed during the APEASE process.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: the (control) arm will include an informational CRC screening brochure developed by the American Cancer Society plus a FIT kit distributed by the barbers.
Study: NCT05223426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: A cognitive training program will be individually developed for each participant based on baseline neuropsychological tests. It will include: Computerized cognitive training: this training include: the Dual-Task, the Stroop and the N-Back task. The tasks are accompanied by feedback based on the participant's responses (e.g., progress graph, feedback, etc.). In order to promote participants' learning, the level of difficulty of the tasks increased as training sessions progressed. Two sets of stimuli will be used to maximize the generalization of learning. Memory training: This training is adapted from the MEMO+ training program (Belleville et al., 2018). These sessions, also home-based, will be done through online video and are covering a variety of topics: memory (normal aging, mnemonic strategies), attention, aging, etc. Each week, participants will be asked to complete the equivalent of 6 training sessions of 15 minutes each, for a total of 1h30 per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: A cognitive training program will be individually developed for each participant based on baseline neuropsychological tests. It will include: Computerized cognitive training: this training include: the Dual-Task, the Stroop and the N-Back task. The tasks are accompanied by feedback based on the participant's responses (e.g., progress graph, feedback, etc.). In order to promote participants' learning, the level of difficulty of the tasks increased as training sessions progressed. Two sets of stimuli will be used to maximize the generalization of learning. Memory training: This training is adapted from the MEMO+ training program (Belleville et al., 2018). These sessions, also home-based, will be done through online video and are covering a variety of topics: memory (normal aging, mnemonic strategies), attention, aging, etc. Each week, participants will be asked to complete the equivalent of 6 training sessions of 15 minutes each, for a total of 1h30 per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will be asked to continue the care and follow-up as usually planned with the attending cardiologist. Apart from weekly follow-ups with the research team member, no changes will be made to the participant's medical care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will be asked to continue the care and follow-up as usually planned with the attending cardiologist. Apart from weekly follow-ups with the research team member, no changes will be made to the participant's medical care.
Study: NCT05585749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Based Relaxation Program
Description: Virtual Reality Based Relaxation Program
Study: NCT04613986

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: therapeutic plasmaexchnage
Description: established method to exchange plasma (in order to remove injurious disease mediators, e.g. antibodies) or to replace consumed factors (e.g. vWF cleaving proteases)